Navigation Links
WebMD Announces First Quarter Financial Results
Date:5/6/2008

Traffic Reached Record Levels of 51.9 Million Unique Monthly Users and 1.2

Billion Quarterly Page Views

NEW YORK, May 6 /PRNewswire-FirstCall/ -- WebMD Health Corp. (Nasdaq: WBMD) today announced financial results for the three months ended March 31, 2008.

"Our Company reached several important milestones this quarter, as WebMD continued to consolidate its position as the leading source of health information for both consumers and health care professionals," said Wayne Gattinella, President and CEO. "We believe that the long-term value of our franchise will continue to increase as we expand our distribution footprint and deliver the full spectrum of online health solutions that the marketplace is steadily evolving towards."

Financial Summary

Revenue for the first quarter was $81.7 million compared to $71.9 million in the prior year period, an increase of 14%. Earnings before interest, taxes, depreciation, amortization, and other non-cash items ("Adjusted EBITDA") for the first quarter increased 25% to $15.8 million or $0.27 per share compared to $12.6 million or $0.21 per share in the prior year period.

Loss from continuing operations and net loss for the first quarter was $(23.3) million or $(0.40) per share, which includes a $27.4 million impairment charge related to a reduction in fair value of the Company's auction rate securities investments. Excluding the impairment, income from continuing operations and net income was $4.1 million or $0.07 per share for the first quarter compared to $0.7 million or $0.01 per share in the prior year period.

Operating Highlights

Online Services segment revenue was $78.4 million for the first quarter compared to $68.4 million in the prior year period, an increase of 15%. Advertising and sponsorship revenue increased 18% to $56.1 million. Private portal licensing revenue increased 9% to $21.9 million. Online Services segment Adjusted EBITDA increased 2 2008 2007

ASSETS

Current assets:

Cash and cash equivalents $159,831 $213,753

Marketable securities 141,044 80,900

Accounts receivable, net 73,861 86,081

Current portion of prepaid

advertising 2,275 2,329

Due from HLTH - 1,153

Other current assets 8,837 10,840

Total current assets 385,848 395,056

Property and equipment, net 46,995 48,589

Prepaid advertising 3,017 4,521

Goodwill 221,429 221,429

Intangible assets, net 33,766 36,314

Other assets 10,889 12,955

$701,944 $718,864

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accrued expenses $16,731 $26,498

Deferred revenue 88,114 76,401

Due to HLTH 207 -

Total current liabilities 105,052 102,899

Other long-term liabilities 9,033 9,210

Stockholders' equity 587,859 606,755

$701,944 $718,864

WEBMD HEALTH CORP.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands, unaudited)

Year Ended

March 31,

2008 2007

Cash flows from operating activities:

Net income (loss) $(23,335) $706

Adjustments to reconcile net income to

net cash provided by operating activities:

Loss from discontinued operations, net

of tax - 29

Depreciation and amortization 6,785 5,991

Non-cash advertising 1,558 2,320

Non-cash stock-based compensation 3,712 5,363

Deferred income taxes 2,415 78

Impairment of auction rate securities 27,406 -

Changes in operating assets and

liabilities:

Accounts receivable 12,220 2,185

Other assets (164) (66)

Accrued expenses and other

long-term liabilities (8,949) (11,545)

Due to HLTH 1,329 228

Deferred revenue 11,714 7,678

Net cash provided by

continuing operations 34,691 12,967

Net cash provided by

discontinued operations - 54

Net cash provided by

operating activities 34,691 13,021

Cash flows from investing activities:

Proceeds from maturities and sales

of available-for-sale securities 40,350 28,122

Purchases of available-for-sale

securities (127,900) (48,632)

Purchases of property and equipment (2,637) (4,762)

Cash received from sale of business,

net of fees 985 -

Net cash used in investing

activities (89,202) (25,272)

Cash flows from financing activities:

Proceeds from issuance of common stock 589 4,458

Net cash transfers with HLTH - 145,257

Net cash provided by

financing activities 589 149,715

Net (decrease) increase in cash and

cash equivalents (53,922) 137,464

Cash and cash equivalents at beginning of

period 213,753 44,660

Cash and cash equivalents at end of period $159,831 $182,124

FINANCIAL GUIDANCE SUMMARY

2008 Financial Guidance

(in millions, except per share amounts)

Year Ended

December 31, 2008

Range

Revenue $380.0 $395.0

Earnings before interest, taxes,

depreciation, amortization and

other non-cash items ("Adjusted

EBITDA") (a) $97.5 $107.5

Adjusted EBITDA per diluted common

share $1.57 $1.73

Interest, taxes, depreciation,

amortization and other non-cash

items (b)

Interest income $10.0 $11.0

Depreciation and amortization $(31.0) $(29.0)

Non-cash advertising $(5.0) $(5.0)

Non-cash stock-based compensation $(22.0) $(21.0)

Impairment of auction rate

securities $(27.4) $(27.4)

Income tax provision (c) $(20.0) $(26.0)

Net income $2.1 $10.1

Net income per common share:

Basic $0.04 $0.17

Diluted $0.03 $0.16

Net income, excluding impairment

of auction rate securities of

($27.4) (d) $29.5 $37.5

Net income per common share,

excluding impairment of auction

rate securities

Basic $0.50 $0.64

Diluted $0.48 $0.60

Weighted-average shares

outstanding used in computing net

income per common share:

Basic 59.0 59.0

Diluted 62.0 62.0

Notes:

(a) See Annex A - Explanation of Non-GAAP Financial Measures

(b) Reconciliation of Adjusted EBITDA to net income

(c) Income tax rate for Q2 to Q4 2008 is estimated to be

approximately 41% of pretax income. The income tax provision excludes

any benefit relating to any reversal in 2008 of the valuation

allowance against deferred tax assets.

(d) Impairment of auction rate securities recorded in Q1 2008.

Additional Information

-- Quarterly distribution of revenue is estimated to be approximately

$81.7 in Q1, $88 to $90 in Q2, $100 to $104 in Q3 and $110 to $119 in

Q4

-- Adjusted EBITDA as a percentage of revenue is estimated to be

approximately 19% in Q1, 22% to 23% in Q2, 27% to 28% in Q3 and 32% to

35% in Q4

-- Net Income (loss) as a percentage of revenue is estimated to be

approximately (29.0%) in Q1, 6.0% to 7.0% in Q2, 9.0% to 11.0% in Q3

and 10.0% to 14.0% in Q4

ANNEX A

Explanation of Non-GAAP Financial Measures

(All dollar amounts in thousands)

The accompanying WebMD Health Corp. press release and financial tables include both financial measures in accordance with U.S. generally accepted accounting principles, or GAAP, as well as non-GAAP financial measures. The non-GAAP financial measures represent earnings before interest, taxes, depreciation, amortization and other non-cash items (which we refer to as "Adjusted EBITDA") and related per share amounts. Adjusted EBITDA should be viewed as supplemental to, and not as an alternative for, "income (loss) from continuing operations" calculated in accordance with GAAP. The tables attached to the accompanying press release include reconciliations of non-GAAP financial measures to GAAP financial measures.

Adjusted EBITDA is used by WebMD's management as an additional measure of WebMD's overall performance and its reporting segments' performance for purposes of business decision-making, including developing budgets, managing expenditures, and evaluating potential acquisitions or divestitures. Period-to-period comparisons of Adjusted EBITDA help WebMD's management identify additional trends in WebMD's and its reporting segments' financial results that may not be shown solely by period-to-period comparisons of income (loss) from continuing operations. In addition, WebMD uses Adjusted EBITDA in the incentive compensation programs applicable to many of its employees in order to evaluate WebMD's performance. WebMD management recognizes that Adjusted EBITDA has inherent limitations because of the excluded items, particularly those items that are recurring in nature. In order to compensate for those limitations, management also reviews the specific items that are excluded from Adjusted EBITDA, but included in income (loss) from continuing operations, as well as trends in those items. The amounts of those items are set forth, for the applicable periods, in the reconciliations of Adjusted EBITDA to net income (loss) from continuing operations that accompany our press releases containing non-GAAP financial measures, including the reconciliations contained in the tables attached to the accompanying press release.

WebMD believes that the presentation of Adjusted EBITDA is useful to investors in their analysis of WebMD's results for reasons similar to the reasons why WebMD's management finds it useful and because it helps facilitate investor understanding of decisions made by WebMD's management in light of the performance metrics used in making those decisions. In addition, as more fully described below, WebMD believes that providing Adjusted EBITDA, together with a reconciliation of Adjusted EBITDA to income (loss) from continuing operations, helps investors make comparisons between WebMD and other companies that may have different capital structures, different effective income tax rates and tax attributes, different capitalized asset values and/or different forms of employee compensation. However, Adjusted EBITDA is intended to provide a supplemental way of comparing WebMD with other public companies and is not intended as a substitute for comparisons based on "income (loss) from continuing operations" or "net income" calculated in accordance with GAAP. In making any comparisons to other companies, investors need to be aware that companies use different non-GAAP measures to evaluate their financial performance. Investors should pay close attention to the specific definition being used and to the reconciliation between such measures and the corresponding GAAP measures provided by each company under applicable SEC rules.

The following is an explanation of the items excluded by WebMD from Adjusted EBITDA but included in income (loss) from continuing operations:

-- Depreciation and Amortization. Depreciation and amortization expense

is a non-cash expense relating to capital expenditures and intangible

assets arising from acquisitions that are expensed on a straight-line

basis over the estimated useful life of the related assets. WebMD

excludes depreciation and amortization expense from Adjusted EBITDA

because it believes (i) the amount of such expenses in any specific

period may not directly correlate to the underlying performance of

WebMD's business operations and (ii) such expenses can vary

significantly between periods as a result of new acquisitions and full

amortization of previously acquired tangible and intangible assets.

Accordingly, WebMD believes this exclusion assists management and

investors in making period-to-period comparisons of operating

performance. Investors should note that use of tangible and intangible

assets contributed to revenue in the periods presented and will

contribute to future revenue generation and should also note that such

expenses will recur in future periods.

-- Stock-Based Compensation Expense. Stock-based compensation expense is

a non-cash expense arising from the grant of stock-based awards to

employees. WebMD believes that excluding the effect of stock-based

compensation from Adjusted EBITDA assists management and investors in

making period-to-period comparisons in its operating performance

because it believes (i) the amount of such expenses in any specific

period may not directly correlate to the underlying performance of

WebMD's business operations and (ii) such expenses can vary

significantly between periods as a result of the timing of grants of

new stock-based awards, including grants in connection with

acquisitions. Additionally, WebMD believes that excluding stock-based

compensation from Adjusted EBITDA assists management and investors in

making meaningful comparisons between WebMD's operating performance and

the operating performance of other companies that may use different

forms of employee compensation or different valuation methodologies for

their stock-based compensation. Investors should note that stock-based

compensation is a key incentive offered to employees whose efforts

contributed to the operating results in the periods presented and are

expected to contribute to operating results in future periods.

Investors should also note that such expenses will recur in the future.

Stock-based compensation expenses included in the Statement of

Operations are summarized as follows:

Three Months Ended

March 31,

2008 2007

Non-cash stock-based compensation

included in:

Cost of operations $(1,119) $(1,578)

Sales and marketing $(1,138) $(1,258)

General and administrative $(1,455) $(2,527)

-- Non-Cash Advertising Expense. This expense relates to the usage of

non-cash advertising obtained from News Corporation ("Newscorp") in

exchange for equity securities issued by our parent, HLTH Corporation

in 2000. The advertising is available only on various Newscorp

properties, primarily its television network and cable channels without

any cash cost to WebMD. The amount of advertising that can be used in

any year is subject to annual contractual limitation and expires in

2009. WebMD does not incur any other cash expenses related to airing of

television advertising. WebMD excludes this expense from Adjusted

EBITDA (i) because it is a non-cash expense, (ii) because it is

incremental to other non-television cash advertising expense that WebMD

otherwise incurs, (iii) because WebMD has not and believes it will not

incur cash expenses relating to television advertising in the future

and (iv) to assist management and investors in comparing its operating

results over multiple periods. Investors should note that it is likely

that WebMD derives some benefit from such advertising and that such

expenses will recur in the future. Non-cash advertising expenses

included in the Consolidated Statement of Operations in Sales and

Marketing expense were $1,558 and $2,320 for the three months ended

March 31, 2008 and 2007, respectively.

-- Interest Income. Interest income is associated with the level of

marketable debt securities and other interest bearing accounts in which

WebMD invests. Interest income varies over time due to varying levels

of securities available for investment. Transactions that WebMD has

entered into in recent periods that have impacted securities available

for investment include the initial public offering of equity in WebMD

and acquisitions of other companies for varying amounts of cash since

our initial public offering. Additional financing transactions as well

as potential acquisitions that WebMD may enter into in the future could

impact the levels and timing of securities available for investment.

WebMD excludes interest income from Adjusted EBITDA (i) because it is

not directly attributable to the performance of WebMD's business

operations and, accordingly, its exclusion assists management and

investors in making period-to-period comparisons of operating

performance and (ii) to assist management and investors in making

comparisons to companies with different capital structures. Investors

should note that interest income will recur in future periods.

-- Income Tax Provision. WebMD had a net operating loss (NOL)

carryforward of approximately $270,000 as of the year ended December

31, 2007. WebMD maintained a full valuation allowance on these NOL

carryforwards until the fourth quarter of 2007, at which time a portion

of the valuation allowance was reversed after consideration of the

relevant factors. The related valuation allowances are either reversed

through the income statement, additional paid-in capital, or reversed

to goodwill, to the extent those tax benefits were acquired through

business combinations. The timing of such reversals has not been

consistent and as a result, WebMD's income tax expense can fluctuate

significantly from period to period in a manner not directly related to

WebMD's operating performance. WebMD excludes the income tax provision

from Adjusted EBITDA (i) because it believes that the income tax

provision is not directly attributable to the underlying performance of

WebMD's business operations and, accordingly, its exclusion assists

management and investors in making period-to-period comparisons of

operating performance and (ii) to assist management and investors in

making comparisons to companies with different tax attributes.

Investors should note that income tax provision7% to $16.5 million compared to $13.0 million in the prior year period.

Traffic to the WebMD Health Network continued to expand with the average number of unique users reaching a record 51.9 million per month and total traffic of 1.2 billion page views during the first quarter, increases of 25% and 24%, respectively, from a year ago. Excluding the prior year period's traffic from AOL (which ceased to be part of The WebMD Health Network on April 30, 2007), the average monthly unique users of the WebMD Health Network increased 29% and page view traffic increased 27%. In the first quarter, 1.1 million continuing medical education (CME) programs were completed on the WebMD Professional Network, an increase of 64% from the prior year period.

WebMD continued to expand its base of large employers and health plans utilizing its private Health and Benefits portals during the first quarter, bringing total platform customers to 122 from 103 a year ago. The installed base of companies licensing the WebMD private portal platform now includes: Newell Rubbermaid, Herman Miller, Inc., SummaCare, Inc. and QualCare, Inc.

Publishing and Other Services segment revenue was $3.3 million for the first quarter compared to $3.5 million in the prior year period, a decrease of 7%. Publishing and Other Services segment Adjusted EBITDA was a loss of ($0.8) million compared to a loss of ($0.4) million in the prior year period. WebMD's offline professional medical reference and textbook publication business was sold on December 31, 2007 and is reflected as a discontinued operation in the Company's financial statements for prior periods.

The strength of the WebMD brand continues to expand. WebMD the Magazine is now the third most highly read health magazine, behind only Prevention and Men's Health, according to the 2008 MARS OTC/DTC national media and marketing study released in April.

Investment in Auction Rate Securities

At March 31, 2008, WebMD held auc will recur in future

periods.

-- Other Items. WebMD engages in other activities and transactions that

can impact WebMD's overall income (loss) from continuing operations.

WebMD excludes these other items from Adjusted EBITDA when it believes

these activities or transactions are not directly attributable to the

performance of WebMD's business operations and, accordingly, their

exclusion would assists management and investors in making

period-to-period comparisons of operating performance. Investors

should note that these other items may recur in future periods. In the

accompanying press release and financial tables, WebMD has excluded

loss on the impairment of auction rate securities from Adjusted EBITDA.

tion rate securities (ARS) with a face amount of $168.4 million. The types of ARS investments that WebMD owns are backed by student loans, 97% of which are guaranteed under the Federal Family Education Loan Program (FFELP), and all had credit ratings of AAA or Aaa when purchased. Since February, all auctions involving these securities have failed. The result of a failed auction is that these ARS continue to pay interest in accordance with their terms until the next successful auction; however liquidity will be limited until there is a successful auction or until such time as other markets for these ARS investments develop. It is uncertain when other markets will develop. WebMD has determined that the fair value of the ARS as of March 31, 2008 was $141 million. Accordingly, WebMD has recorded an impairment charge of $27.4 million related to a reduction in fair value of the Company's auction rate securities investments for the quarter ended March 31, 2008.

In addition to its ARS investments, WebMD has approximately $160 million in cash and cash equivalents at March 31, 2008.

Merger with HLTH

As previously announced, HLTH and WebMD entered into a definitive merger agreement on February 20, 2008. The agreement provided that HLTH will be merged into WebMD, with each outstanding share of HLTH common stock to be converted into 0.1979 shares of WebMD common stock and $6.89 in cash, subject to certain adjustments. Completion of the merger is conditioned upon, among other things, approval of the stockholders of both HLTH and WebMD. HLTH and WebMD currently expect to file a preliminary proxy statement/prospectus relating to the merger in the next few weeks and believe that would likely allow them to hold stockholder meetings in September to seek those approvals. However, the ability to schedule these meetings will depend on the timing for closing the sales of HLTH's ViPS and Porex businesses, at least one of which must be completed prior to closing the merger, as well as the timing for completion of SEC review of the proxy statement/prospectus. HLTH is currently in the process of selling the ViPS and Porex businesses, with potential purchasers nearing completion of their due diligence investigations.

Financial Guidance

As announced on April 23, 2008, WebMD currently expects 2008 revenue of $380 to $395 million, assuming the following distribution:

-- Approximately 73% from advertising and sponsorship, with revenue growth

of approximately 21% to 26% over 2007;

-- Approximately 23% from licensing of our private portal products, with

revenue growth of approximately 8% to 10% over 2007; and

-- Approximately 4% from publishing and content syndication revenues.

A schedule providing additional information is attached to this press release.

Analyst and Investor Conference Call

As previously announced, WebMD will hold a conference call with investors and analysts to discuss its first quarter results at 4:45 pm (eastern) today. The call can be accessed at http://www.wbmd.com (in the Investor Relations section). A replay of the audio webcast will be available at the same web address.

About WebMD

WebMD Health Corp. (Nasdaq: WBMD) is the leading provider of health information services, serving consumers, physicians, healthcare professionals, employers and health plans through our public and private online portals and health-focused publications. WebMD Health Corp. is a subsidiary of HLTH Corporation (Nasdaq: HLTH).

The WebMD Health Network includes WebMD Health, Medscape, MedicineNet, eMedicine, eMedicine Health, RxList and theHeart.org.

This press release does not constitute an offer of any securities for sale. In connection with the proposed merger, HLTH and WebMD expect to file, with the SEC, a proxy statement/prospectus as part of a registration statement regarding the proposed transaction. Investors and security holders are urged to read the proxy statement/prospectus because it will contain important information about HLTH and WebMD and the proposed transaction. Investors and security holders may obtain a free copy of the definitive proxy statement/prospectus and other documents when filed by HLTH and WebMD with the SEC at http://www.sec.gov or http://www.hlth.com or http://www.wbmd.com. Investors and security holders are urged to read the proxy statement, prospectus and other relevant material when they become available before making any voting or investment decisions with respect to the merger.

All statements contained in this press release, other than statements of historical fact, are forward-looking statements, including those regarding: expectations regarding the market for WebMD's investments in auction rate securities (ARS); WebMD's future financial results and other measures of WebMD's future performance; market opportunities and WebMD's ability to capitalize on them; the benefits expected from new products or services and from other potential sources of additional revenue; the merger transaction between HLTH and WebMD (the "Merger Transaction"); and the potential sales transactions with respect to ViPS and Porex (the "Potential Sales Transactions"). These statements speak only as of the date of this press release, are based on WebMD's current plans and expectations, and involve risks and uncertainties that could cause actual future events or results to be different than those described in or implied by such forward-looking statements. These risks and uncertainties include those relating to: changes in the markets for ARS; market acceptance of WebMD's products and services; WebMD's relationships with customers and strategic partners; and changes in economic, political or regulatory conditions or other trends affecting the healthcare, Internet and information technology industries. Further information about these matters can be found in our other Securities and Exchange Commission filings. In addition, there can be no assurances regarding: whether HLTH and WebMD will be able to complete the Merger Transaction or as to the timing of such transaction; or whether HLTH will be able to complete the Potential Sales Transactions or as to the timing or terms of such transactions. Except as required by applicable law or regulation, we do not undertake any obligation to update our forward-looking statements to reflect future events or circumstances.

This press release, and the accompanying tables, include both financial measures in accordance with accounting principles generally accepted in the United States of America, or GAAP, as well as certain non-GAAP financial measures. The tables attached to this press release include reconciliations of these non-GAAP financial measures to GAAP financial measures. In addition, an "Explanation of Non-GAAP Financial Measures" is attached to this press release as Annex A.

WebMD(R), WebMD Health(R), Medscape(R), eMedicine(R), MedicineNet(R), RxList(R), Subimo(R), Medsite(R), The Little Blue Book(R) and Summex(R), are trademarks of WebMD Health Corp. or its subsidiaries.

WEBMD HEALTH CORP.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data, unaudited)

Three Months Ended

March 31,

2008 2007

Revenue $81,682 $71,944

Costs and expenses:

Cost of operations 31,570 28,618

Sales and marketing 25,830 22,870

General and administrative 13,775 15,505

Impairment of auction rate securities 27,406 -

Depreciation and amortization 6,785 5,991

Interest income 3,453 1,985

Income (loss) from continuing operations

before income tax provision (20,231) 945

Income tax provision 3,104 210

Income (loss) from continuing operations (23,335) 735

Loss from discontinued operations,

net of tax - (29)

Net income (loss) $(23,335) $706

Basic income (loss) per common share:

Income (loss) from continuing operations $(0.40) $0.01

Loss from discontinued operations - (0.00)

Net Income (loss) $(0.40) $0.01

Diluted income (loss) per common share:

Income (loss) from continuing operations $(0.40) $0.01

Loss from discontinued operations - (0.00)

Net Income (loss) $(0.40) $0.01

Weighted-average shares outstanding used in

computing basic and diluted net income

(loss) per common share:

Basic 57,636 56,976

Diluted 57,636 59,630

WEBMD HEALTH CORP.

CONSOLIDATED SEGMENT INFORMATION

(In thousands, except per share data, unaudited)

Three Months Ended

March 31,

2008 2007

Revenue

Online Services:

Advertising and sponsorship $56,065 $47,421

Licensing 21,923 20,115

Content syndication and other 417 884

Total Online Services 78,405 68,420

Publishing and Other Services 3,277 3,524

$81,682 $71,944

Earnings (loss) before interest, taxes,

depreciation, amortization and other

non-cash items ("Adjusted EBITDA") (a)

Online Services $16,531 $12,992

Publishing and Other Services (754) (358)

15,777 12,634

Adjusted EBITDA per basic common

share $0.27 $0.22

Adjusted EBITDA per diluted common

share ( c ) $0.27 $0.21

Interest, taxes, depreciation, amortization

and other non-cash items (b)

Interest income 3,453 1,985

Depreciation and amortization (6,785) (5,991)

Non-cash advertising (1,558) (2,320)

Non-cash stock-based compensation (3,712) (5,363)

Impairment of auction rate securities (27,406) -

Income tax provision (3,104) (210)

Income (loss) from continuing operations (23,335) 735

Loss from discontinued operations,

net of tax - (29)

Net income (loss) $(23,335) $706

Basic income (loss) per common share:

Income (loss) from continuing

operations $(0.40) $0.01

Loss from discontinued operations - (0.00)

Net Income (loss) $(0.40) $0.01

Diluted income (loss) per common share:

Income (loss) from continuing

operations $(0.40) $0.01

Loss from discontinued operations - (0.00)

Net Income (loss) $(0.40) $0.01

Weighted-average shares outstanding

used in computing basic and diluted net

income (loss) per common share:

Basic 57,636 56,976

Diluted 57,636 59,630

(a) See Annex A - Explanation of Non-GAAP Financial Measures

(b) Reconciliation of Adjusted EBITDA to net income (loss)

(c) Three months ended March 31, 2008 Adjusted EBITDA per share is

calculated based on 59,145 diluted shares.

WEBMD HEALTH CORP.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, unaudited)

March 31, December 31,


'/>"/>

SOURCE WebMD Health Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. WebMD to Present at the Third Annual Needham & Company Internet & Digital Media Conference
2. WebMD Provides Preliminary First Quarter Results and Updates Financial Guidance for 2008
3. HLTH and WebMD Announce First Quarter Earnings Release Date and Conference Call
4. WebMD to Present at the Morgan Stanley Technology Conference
5. HLTH and WebMD Announce Fourth Quarter Earnings Release Date and Conference Call
6. WebMD to Present at Upcoming Investor Conferences
7. WebMD Reports Preliminary Third Quarter Financial Results
8. HLTH Corporation Announces First Quarter Financial Results
9. U.S. Preventive Medicine Announces Investment Banking Team
10. The Lucian Leape Institute at the National Patient Safety Foundation Announces the Appointment of Two New Members
11. NUCRYST Announces First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... that co-occur frequently. While a significant number of women and men with eating ... the trauma itself, that best predicts the development of an eating disorder. ...
(Date:2/8/2016)... ... 08, 2016 , ... GrassrootsHealth published data from its D*action ... diabetes in the GrassrootsHealth cohort with substantially higher vitamin D levels than a ... health,” states Carole Baggerly, Director of GrassrootsHealth, “the safety and benefits of ...
(Date:2/8/2016)... Vegas, Nevada (PRWEB) , ... February 08, 2016 ... ... at RowdMap, Inc., will be speaking on how healthcare companies can use newly ... costs, manage the health of a population and intervene and capture the value ...
(Date:2/8/2016)... ... February 08, 2016 , ... According to research ... U.S. require dental technicians to be certified or obtain continuing education. To increase ... the “What’s In Your Mouth?” campaign to inform dentists and patients about the ...
(Date:2/7/2016)... ... February 07, 2016 , ... ... empowers employers and organizations with the tools and information to lower the costs, ... to cut the cost of providing employee healthcare benefits by as much as ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Feb. 8, 2016 ... "Global Skin Protective Equipment Market 2016-2020" ... http://www.researchandmarkets.com/research/fqx6nz/global_skin ) has announced the addition of ... report to their offering. ... has announced the addition of the "Global ...
(Date:2/8/2016)... 8, 2016   HighPoint Solutions today ... (NRG),s pharmacovigilance technology services division.  NRG is a ... an Oracle Argus Specialized partner, providing drug safety ... companies. --> --> ... sciences capabilities and provides a global scale and ...
(Date:2/8/2016)... http://www.researchandmarkets.com/research/x6mkjm/knee ) has announced ... Market by Product Type (Primary (Cemented & Cementless), ... Eu-5, Japan, Bric, Turkey, Indonesia - Global Analysis ... offering. --> http://www.researchandmarkets.com/research/x6mkjm/knee ) has ... Devices Market by Product Type (Primary (Cemented & ...
Breaking Medicine Technology: